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Background: Intragenic deletions of the dystrophin-encoding and muscular dystrophy-associated DMD gene have
been recently described in gastrointestinal stromal tumor (GIST), rhabdomyosarcoma (RMS) and leiomyosarcoma
(LMS). We evaluated the copy numbers and gene expression levels of DMD in our series of GIST patients who were
already studied with wide genome assays, to investigate more fully a correlation between dystrophin status and
disease annotations.
Findings: Our study highlighted a recurrent intragenic deletion on chromosome X, involving the DMD gene that
codes for human dystrophin in GIST patients. Of 29 KIT/PDGFRA mutant GIST samples, 9 (31%) showed deletions of the
DMD gene, which were focal and intragenic in 8 cases, and involved loss of an entire chromosome in one case
(GIST_188). DMD loss was seen in only 5 patients with metastasis, whereas 18 out of 20 patients with localized disease
had wild-type DMD (P = 0.0004, Fisher exact test). None of the 6 KIT/PDGFRA WT GIST showed DMD alterations.
Conclusions: Our study confirms the presence of DMD deletions only in KIT/PDGFRA mutant GIST and this event is
almost associated with metastatic disease. These findings are, of course, quite preliminary but support development of
potential therapeutic strategies that target and restore DMD function in the treatment of metastatic GIST.
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Intragenic deletions of the dystrophin-encoding and mus-
cular dystrophy-associated DMD gene have been recently
described in many common human mesenchymal tumors,
including gastrointestinal stromal tumor (GIST), rhabdo-
myosarcoma (RMS) and leiomyosarcoma (LMS) which
show myogenic differentiation [1]. In particular, DMD de-
letions were found in 19 of 29 GIST tumors, 3 of 4 RMS
tumors and 3 of 7 LMS tumors. Moreover, DMD deletions
and their protein expression were not found in non-
myogenic cancers, or in benign counterparts of GIST,
RMS and LMS. In GIST, dystrophin is downregulated in
metastatic GIST and primary high-risk GIST, but not in* Correspondence: maria.pantaleo@unibo.it
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unless otherwise stated.low-risk GIST, which implies this downregulation is a late
event in progression of this disease. Finally, dystrophin in-
hibits myogenic sarcoma cell migration, invasion, anchor-
age independence and invadopodia formation; and when
deregulated, dystrophin restoration inhibits invasiveness
and migration in sarcoma cell lines. These data validate
dystrophin as a tumor suppressor and likely anti-metastatic
factor. In light of these findings, we evaluated DMD copy
number and gene expression levels in our series of GIST
patients who had already been studied with wide genome
assays, to investigate more fully the correlation between
dystrophin status and disease annotations.Patient selection and tumor sample collection
Dystrophin status was evaluated using already-available
data from wide genome assays done on tumor speci-
mens collected during surgery and immediately frozen.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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KIT/PDGFRA GIST and 6 with wild-type (WT) KIT/
PDGFRA GIST. Among the KIT/PDGFRA WT GIST
group, 4 cases were SDH deficient and 2 cases were
quadruple KIT/PDGFRA/SDH/BRAF-KRAS-NF1 WT.
Out of all 35 patients, 19 had already been reported [2].
Table 1 shows patients’ clinical and molecular data. TheTable 1 Clinical and molecular data of the patients included i
ID Sex Age DMD Start End Site Disease st
GIST_18 M NA loss ex2 ex7 NA NA
GIST_20 M 38 loss ex2 Small intestine Metastatic
ex8 ex17
GIST_22 F 76 loss ex1 ex44 Stomach NA
GIST_25 M 84 loss ex1 ex17 NA NA
GIST_26 M 49 loss ex1 ex11 Stomach Metastatic
GIST_27 M 52 loss ex1 NA NA
GIST_131 M 58 loss ex3 ex7 Small intestine Metastatic
GIST_174 M 59 loss ex1 ex7 Stomach Metastatic
GIST_188 F 57 loss All
chromosome
Small intestine Metastatic
GIST_02 F 85 wt - - Stomach Localized
GIST_04 M 79 wt - - Stomach Localized
GIST_05 M 68 wt - - Stomach Localized
GIST_08 M 62 wt - - Stomach Localized
GIST_09 M 54 wt - - Stomach Localized
GIST_11 M 65 wt - - Stomach Localized
GIST_12 F 66 wt - - Stomach Localized
GIST_13 M 46 wt - - Small intestine Localized
GIST_14 M 56 wt - - Stomach Metastatic
GIST_15 F 64 wt - - Stomach Localized
GIST_16 F 62 wt - - Stomach Localized
GIST_121 M 72 wt - - Stomach Localized
GIST_124 M 72 wt - - Stomach Localized
GIST_125 F 49 wt - - Stomach Localized
GIST_129 M 60 wt - - Stomach Localized
GIST_130 F 79 wt - - Stomach Localized
GIST_134 F 65 wt - - Stomach Localized
GIST_135 F 60 wt - - Stomach Localized
GIST_136 M 76 wt - - Stomach Localized
GIST_150 F 56 wt - - Stomach Metastatic
GIST_07 F 27 wt - - Stomach Metastatic
GIST_10 M 29 wt - - Stomach Metastatic
GIST_21 F 25 wt - - Stomach NA
GIST_24 F 18 wt - - Stomach Metastatic
GIST_127 F 63 wt - - Ileum Localized
GIST_133 M 57 wt - - Duodenum Localized
Patients with DMD loss are shown in bold.genomic analysis study was approved by local Ethical
Committee.
Copy number analysis
Genomic DNA was extracted with QiaAmp DNA mini
kit (Qiagen, Milan, Italy), labelled and hybridized to SNP
array Genome Wide SNP 6.0 (Affymetrix) followingn the study
atus KIT/PDGFRA Mutational status
KIT exon 11 V559G
KIT exon 11 del MYEQW552–557 Z;
KIT exon 18 A829P
PDGFRA exon 18 D842V
KIT exon 11 del WKV557–559 F
PDGFRA exon 12 V561D
KIT exon 11 del KV558-559 N
KIT exon 11 del V569_Y578
KIT exon 11 L576P
KIT exon 11 N564_L576del; KIT exon 17 p.N822K
KIT exon 11 V560D
KIT exon 9 ins AY502–503
PDGFRA exon 12 ins/del SPDGHE566–571RIQ
KIT exon 11 V559D
KIT exon 11 ins TQLPYDHKWEFP574–585 at P585
KIT exon 11 del WK557–558
PDGFRA exon 14 K646E
KIT exon 11 V559D
KIT exon 11 hom. del WK557–558
PDGFRA exon 18 del DIMH842-845
KIT exon 11 L576P
KIT exon 11 V559D
KIT exon 11 ins 1765–1766
KIT exon 11 W557R
KIT exon 11 del/ins Y553–V559L
KIT exon 9 ins A502_Y503
KIT exon 11 homoz. V559D
KIT exon 11 del W557_E561
PDGFRA exon 18 D842V
KIT exon 11 P551_E554del
KIT/PDGFRA wild-type (SDH deficient)
KIT/PDGFRA wild-type (SDH deficient)
KIT/PDGFRA wild-type (SDH deficient)
KIT/PDGFRA wild-type (SDH deficient)
Quadruple wild-type (KIT/PDGFRA/SDH/BRAF-KRAS-NF1 wild-type).
Quadruple wild-type (KIT/PDGFRA/SDH/BRAF-KRAS-NF1 wild-type).
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formed by Contrast QC and MAPD calculation. Copy
number analysis was performed by Genotyping Console
and visualized with Chromosome Analysis Suite Soft-
ware (Affymetrix). Hidden Markov Model algorithm was
used to detect amplified and deleted segments.
RNA sequencing
Whole-transcriptome sequencing was performed on RNA
isolated from fresh-frozen tumor tissue with the RNeasyFigure 1 DMD deletions and gene expression in KIT/PDGFRA mutant
arrays on the X chromosome, showing focal losses and deletion of 1 entire
genomic losses of DMD gene, located on the reverse X chromosome stran
from RNA sequencing of the samples that carry DMD deletions. All cases respin-column method (Qiagen). Whole-transcriptome RNA
libraries were prepared in accordance with Illumina’s
TruSeq RNA Sample Prep v2 protocol (Illumina, San
Diego, California). Paired-end libraries were sequenced at
2 × 75bp read length using Illumina Sequencing by synthesis
(SBS) technology. Averages of 85 million reads per sample
were analyzed. Mapping on the human reference genome
was done with TopHat/BowTie software, while expression
level of the DMD gene was expressed as number of mapped
reads.IST samples. (A) Signal Log2 Ratio of copy number data from SNP 6.0
chromosome arm. (B) Graphical representation of sizes of the
d. (C) DMD expression showed as average number of mapped reads
tain the expression of the short isoform starting from exon 63.
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The genome-wide analysis of our series highlighted a
recurrent intragenic deletion on chromosome X for
the DMD gene, which codes for human dystrophin.
Nine of the 29 KIT/PDGFRA mutant GIST (31%)
showed DMD gene deletions (Figure 1A), which were
focal and intragenic in 8 cases, and involved loss of a
whole chromosome in one case (GIST_188; Figure 1B).
None of the 6 KIT/PDGFRA WT GIST samples had
DMD alterations.
As DMD is an X-linked gene, deletions were nullizy-
gous in males and heterozygous in females. All focal
events involved the 5′ portion of the gene, with the
region between exon 2 and exon 7 as the most recur-
rently involved, and an average deletion size of 770 Mb.
RNA-sequencing performed on 3 out of 9 cases with
deletions showed that the genomic losses abrogated ex-
pression of the largest DMD transcript, while preserving
expression of the short isoform, with a transcription
start site at exon 63 (Figure 1C).
Patients with KIT/PDGFRA mutant GIST tended to
have higher frequency of DMD deletions in more ad-
vanced cases, as DMD loss was seen only in the 5 pa-
tients with metastasis, whereas 18 out of the 20 patients
with localized disease wild-type DMD (Table 1; P =
0.0004, Fisher exact test).
Our study confirms the presence of DMD deletions in
KIT/PDGFRA mutant GIST. In particular we also ob-
served that this molecular event is associated with more
advanced clinical disease such as metastatic tumors. Al-
though these findings are quite preliminary they suggest
potential therapeutic strategies that target and restore
DMD function in treating metastatic GIST. Larger stud-
ies are necessary to correlate DMD status and specific
mutations of KIT/PDGFRA receptors to explore novel
therapies for GIST that present primary resistance or
that initially responds to imatinib but later progresses
[3]. As is well known, molecular mechanisms of second-
ary resistance are various and heterogeneous, the most
common being the acquisition of secondary KIT/
PDGFRA mutations or selection of sub-clones with re-
sistant mutations [4]. In our series, of 7 patients who
presented primary mutations in KIT exon 11, 2 also had
secondary mutations, in KIT exon 17 or KIT exon 18.
The 2 patients with mutations in PDGFRA had them in
exon 18 D842V or exon 12. The small series does not
permit any conclusive considerations on the correlation
of DMD involvement with KIT/PDGFRA kinase geno-
type. But as the clinical use of sunitinib and regorafenib
after imatinib failure does not completely cover the mo-
lecular landscape of the progressing GIST, a novel ap-
proach that targets dystrophin deregulation may have
relevance in GIST treatment. Moreover, compared with
KIT/PDGFRA mutant GIST, in our series all patientswith KIT/PDGFRA WT GIST—including 4 who were
SDH deficient and 2 who had quadruple KIT/PDGFRA/
SDH/BRAF-KRAS-NF1 WT did not present dystrophin
deregulation, even those with metastasis, which con-
firms once again that KIT/PDGFRA WT GIST should
be considered a distinct disease in molecular back-
ground and clinical presentation [5].
Conclusion
In conclusion, deregulation of dystrophin seems to be
associated with GIST progression and more data should
be accumulated in order to define it as a therapeutic
target.
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